I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| B cell | 5 studies | 17% ± 2% | |
| astrocyte | 5 studies | 26% ± 11% | |
| oligodendrocyte precursor cell | 5 studies | 27% ± 7% | |
| plasmacytoid dendritic cell | 5 studies | 19% ± 4% | |
| natural killer cell | 4 studies | 19% ± 1% | |
| CD16-negative, CD56-bright natural killer cell, human | 4 studies | 18% ± 2% | |
| microglial cell | 4 studies | 18% ± 3% | |
| oligodendrocyte | 4 studies | 23% ± 7% | |
| naive B cell | 4 studies | 16% ± 1% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 21% ± 3% | |
| regulatory T cell | 3 studies | 16% ± 1% |
